MARKET

CURX

CURX

CURANEX PHARMACEUTICALS INC
NASDAQ
0.3325
+0.0305
+10.10%
After Hours: 0.3435 +0.011 +3.31% 16:20 05/20 EDT
OPEN
0.3007
PREV CLOSE
0.3020
HIGH
0.3400
LOW
0.3000
VOLUME
123.73K
TURNOVER
--
52 WEEK HIGH
9.18
52 WEEK LOW
0.2620
MARKET CAP
9.43M
P/E (TTM)
-1.2843
1D
5D
1M
3M
1Y
5Y
1D
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
PR Newswire · 2d ago
Weekly Report: what happened at CURX last week (0511-0515)?
Weekly Report · 2d ago
Curanex Advances Phyto-N Program and Expands Indications
TipRanks · 6d ago
Curanex Pharmaceuticals Q1 EPS $(0.11) Down From $(0.01) YoY
Benzinga · 6d ago
Curanex Continues To Advance Phyto-N As Lead Development Candidate, With Ulcerative Colitis As Initial Target Indication; Co. Prepares Phyto-N For Planned IND Submission In Q4 Of 2026
Benzinga · 6d ago
CURANEX PHARMACEUTICALS: ADVANCING PHYTO-N TOWARD A PLANNED INVESTIGATIONAL NEW DRUG SUBMISSION TO FDA FOR ULCERATIVE COLITIS IN Q4 2026
Reuters · 6d ago
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
Barchart · 6d ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
PR Newswire · 05/12 22:08
More
About CURX
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).

Webull offers Curanex Pharmaceuticals Inc stock information, including NASDAQ: CURX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CURX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CURX stock methods without spending real money on the virtual paper trading platform.